Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Baek Urges Review of Drug Price Premiums Excluding Korean-Made APIs From Affiliates

Whether drug ingredients made in South Korea qualify for preferential pricing when the ingredient producer and the finished drug’s marketing authorization holder are separate companies came under scrutiny at a National Assembly audit in Seoul on October 16. The debate concerns how the pricing system recognizes domestic manufacturing across pharmaceutical groups. At issue is whether eligibility…

Rep. Baek Sun-hee from the Rebuilding Korea Party has called for a review of drug price premiums, focusing on whether Korean-made APIs qualify for preferential pricing when the ingredient producer and the finished drug’s marketing authorization holder are separate companies. During a National Assembly audit in Seoul on October 16, Baek questioned why no companies currently meet the requirement tying API production to the finished drug authorization holder’s own manufacturing facility.

This debate stems from concerns about the eligibility rules reflecting production divided among affiliated companies and ensuring continued compliance.

Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at koreaittimes.com →

More in Health & Medicine

More from Saturday 17 October →